Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...

Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...

'Mad Money' host Jim Cramer weighs in on stocks including: AES, InterDigital, Infleqtion, Netskope, and Biogen.

Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...